The FDA’s green light for a Phase II trial (JSKN003-202) of JSKN003 accelerates efforts to address platinum-resistant ovarian ...

Results from the long-term extension of the Phase III TRAILBLAZER-ALZ 2 trial (NCT04437511) showed sustained benefits with ...

In this video interview, Michael Miller, chief operating officer at Quanterix, discusses how biopharma companies—especially ...

New statistical frameworks such as net treatment benefit offer a multidimensional approach to evaluating efficacy, safety, ...

In this video interview, Michael Miller, chief operating officer at Quanterix, discusses how the use of biomarkers is ...

In this video interview, Michael Miller, chief operating officer at Quanterix, outlines key technical and regulatory ...

In this pilot episode of the Applied Clinical Trials Brief, we examine the renewed push for placebo-controlled vaccine trials ...

In the ongoing Phase II CRDF-004 trial, onvansertib plus standard-of-care showed a 49% confirmed ORR and early PFS benefit in ...

In the BOHEMIA study, once-monthly ivermectin over 3 months significantly reduced malaria incidence versus albendazole in children aged 5 to 15 years, supporting its role as a novel vector-control ...

VYNE Therapeutics will terminate its Phase IIb trial of topical Repibresib gel in nonsegmental vitiligo after failing to meet ...

In this video interview, Michael Miller, chief operating officer at Quanterix, highlights neurology and oncology as two ...

In this video interview, Kate Gallin Heffernan, life sciences attorney at Epstein Becker Green, advises clinical research ...